Carastock.

Cara Therapeutics Stock Earnings. The value each CARA share was expected to gain vs. the value that each CARA share actually gained. Cara Therapeutics ( CARA) reported Q3 2023 earnings per share (EPS) of -$0.52, meeting estimates of -$0.52 by 0.60%. In the same quarter last year, Cara Therapeutics 's earnings per share (EPS) was -$0.43.The current Cara Therapeutics [ CARA] share price is $0.98. The Score for CARA is 17, which is 66% below its historic median score of 50, and infers higher risk than normal. CARA is currently trading in the 10-20% percentile range relative to its historical Stock Score levels.Oct 23, 2023 · Cara Therapeutics Reports Second Quarter 2023 Financial Results. – 2Q23 total revenue of $6.9M including collaborative revenue of $5.4M from the Company’s share of profit of KORSUVA ® (difelikefalin) injection – – Demand for KORSUVA injection accelerating with 46% increase in vial orders quarter to quarter – – 2024 ESRD PPS ... Nov 13, 2023 · Pruritus is defined as an unpleasant sensation that provokes the desire to scratch, but we know it’s much more than that. Chronic pruritus can be a devastating, disabling, and burdensome condition that significantly impairs quality of life. The millions of people who suffer from pruritus deserve relief.

Cara Therapeutics Inc (CARA) stock is trading at $5.05 as of 2:41 PM on Friday, Mar 31, an increase of $0.16, or 3.27% from the previous closing price of $4.89. The stock has traded between $4.90 and $5.06 so far today. Volume today is light. So far 469,000 shares have traded compared to average volume of 834,454 shares.Cara Therapeutics (CARA) Options Chain & Prices. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Get daily stock ideas from top-performing Wall Street analysts.

Cara Therapeutics Inc (CARA) stock is trading at $5.05 as of 2:41 PM on Friday, Mar 31, an increase of $0.16, or 3.27% from the previous closing price of $4.89. The stock has traded between $4.90 and $5.06 so far today. Volume today is light. So far 469,000 shares have traded compared to average volume of 834,454 shares.Nov 29, 2023 · Cara Therapeutics Inc is an emerging biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus.

According to the issued ratings of 6 analysts in the last year, the consensus rating for Cara Therapeutics stock is Moderate Buy based on the current 1 sell rating, 1 hold rating and 4 buy ratings for CARA. The average twelve-month price prediction for Cara Therapeutics is $15.86 with a high price target of $25.00 and a low price target of $4.00.Where the stock market will trade today based on Dow Jones Industrial Average, S&P 500 and Nasdaq-100 futures and implied open premarket values. Commodities, currencies and global indexes also shown.Cara Therapeutics, Inc. Common Stock. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is ... Cara Therapeutics Inc’s ( CARA) price is currently down 34.15% so far this month. During the month of March, Cara Therapeutics Inc’s stock price has reached a high of $10.39 and a low of $6.58. Over the last year, Cara Therapeutics Inc has hit prices as high as $13.97 and as low as $7.40. Year to date, Cara Therapeutics Inc’s stock is ...

The current Cara Therapeutics [ CARA] share price is $1.09. The Score for CARA is 25, which is 50% below its historic median score of 50, and infers higher risk than normal. CARA is currently trading in the 20-30% percentile range relative to its historical Stock Score levels.

Mar. 7, 2023, 07:18 AM. Cara Therapeutics, Inc. (NASDAQ:CARA) posted downbeat Q4 results. Cara Therapeutics posted a Q4 loss of $0.56 per share, versus market expectations of $0.32 per share. The ...

Dec 1, 2023 · According to the issued ratings of 6 analysts in the last year, the consensus rating for Cara Therapeutics stock is Moderate Buy based on the current 1 sell rating, 1 hold rating and 4 buy ratings for CARA. The average twelve-month price prediction for Cara Therapeutics is $15.86 with a high price target of $25.00 and a low price target of $4.00. Cara Therapeutics Inc’s trailing 12-month revenue is $27.2 million with a -410.9% profit margin. Year-over-year quarterly sales growth most recently was -70.0%. Analysts expect adjusted earnings to reach $-1.998 per share for the current fiscal year. Cara Therapeutics Inc does not currently pay a dividend.May 25, 2023 at 3:40 AM · 3 min read. You may think that with a price-to-sales (or "P/S") ratio of 4.4x Cara Therapeutics, Inc. ( NASDAQ:CARA) is a stock to potentially avoid, seeing as almost ...Stock Price Forecast. According to 8 stock analysts, the average 12-month stock price forecast for CARA stock stock is $15.13, which predicts an increase of ...Nov 13, 2023 · Pruritus is defined as an unpleasant sensation that provokes the desire to scratch, but we know it’s much more than that. Chronic pruritus can be a devastating, disabling, and burdensome condition that significantly impairs quality of life. The millions of people who suffer from pruritus deserve relief.

What's Happening with CARA Stock Today Cara Therapeutics Inc (CARA) stock is down -4.28% while the S&P 500 has gained 1.3% as of 12:31 PM on Wednesday, Apr 27. CARA is down -$0.45 from the previous closing price of $10.51 on volume of 212,841 shares. Over the past year the S&P 500 has gained 1.02% while CARA is down -61.46%.Recent price changes and earnings estimate revisions indicate this would be a good stock for momentum investors with a Momentum Score of A. Style Scorecard.Trailing 12-Months. Asset Growth. -40.69%. Trailing 12-Months. Cara Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven ... 22 thg 3, 2023 ... Cara Therapeutics Inc Stock Price: Bottom Line. As of March 22, 2023, Cara Therapeutics Inc's stock price is $5.18, which is down 5.65% from its ...Cara Therapeutics Reports Second Quarter 2023 Financial Results. – 2Q23 total revenue of $6.9M including collaborative revenue of $5.4M from the Company’s share of profit of KORSUVA ® (difelikefalin) injection – – Demand for KORSUVA injection accelerating with 46% increase in vial orders quarter to quarter – – 2024 ESRD PPS ...

30 thg 10, 2022 ... SOP (Standar Operasional Prosedur) stock opname di apotek pada umumnya · Menghentikan pergerakan barang masuk dan keluar apotek saat stock ...

The above table shows the PS ratio for CARA vs its peers. Here we also display the market cap and forecasted growth for additional consideration. Price-To-Sales vs Peers: CARA is good value based on its Price-To-Sales Ratio (2.8x) compared to the peer average (7.9x).CARA Stock 12 Months Forecast. $14.10. (1230.19% Upside) Based on 5 Wall Street analysts offering 12 month price targets for Cara Therapeutics in the last 3 months. The average price target is $14.10 with a high forecast of $25.00 and a low forecast of $3.50. The average price target represents a 1230.19% change from the last price of $1.06. Stock split BBCA dengan rasio 1:5, artinya 1 saham yang ada saat ini dipecah menjadi 5 saham baru. Jumlah saham yang beredar semakin banyak, harga makin terjangkau. Nilai nominal per saham BBCA dari Rp 62,5 menjadi Rp 12,5. Sedangkan jumlah saham BCA sebelum stock split sebanyak 24,65 miliar saham menjadi 123,27 …Find the latest Cara Therapeutics, Inc. (CARA) stock quote, history, news and other vital information to help you with your stock trading and investing.In 2022, CARA's revenue was $41.87 million, an increase of 81.81% compared to the previous year's $23.03 million. Losses were -$85.47 million, -3.35% less than ...Cara Therapeutics Inc’s ( CARA) price is currently down 49.02% so far this month. During the month of March, Cara Therapeutics Inc’s stock price has reached a high of $10.39 and a low of $5.17. Over the last year, Cara Therapeutics Inc has hit prices as high as $13.97 and as low as $5.24. Year to date, Cara Therapeutics Inc’s stock is ...According to the issued ratings of 6 analysts in the last year, the consensus rating for Cara Therapeutics stock is Moderate Buy based on the current 1 sell rating, 1 hold rating and 4 buy ratings for CARA. The average twelve-month price prediction for Cara Therapeutics is $15.86 with a high price target of $25.00 and a low price target of $4.00.Browse Getty Images' premium collection of high-quality, authentic Cara stock photos, royalty-free images, and pictures. Cara stock photos are available in ...

Over the last four quarters, the company has surpassed consensus EPS estimates two times. Cara, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $3.26 ...

Find out the direct holders, institutional holders and mutual fund holders for Cara Therapeutics, Inc. (CARA).

Research Reports. SEC Filings. Insider Monkey. Get the latest Cara Therapeutics, Inc. (CARA) stock news and headlines to help you in your trading and investing decisions.Get the latest Cara Therapeutics Inc. (CARA) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals.Nov 29, 2023 · Cara Therapeutics Inc is an emerging biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. 218.25%. Free cash flow. Amount of cash a business has after it has met its financial obligations such as debt and outstanding payments. -8.64M. 47.45%. Get the latest Cara …As of Friday, March 03, Cara Therapeutics Inc’s CARA share price has surged by 4.90%, which has investors questioning if this is right time to sell.See the latest Carasent ASA stock price (XOSL:CARA), related news, valuation, dividends and more to help you make your investing decisions.The current Cara Therapeutics [ CARA] share price is $0.98. The Score for CARA is 17, which is 66% below its historic median score of 50, and infers higher risk than normal. CARA is currently trading in the 10-20% percentile range relative to its historical Stock Score levels.CARA stock returns are also predicted based on historical data. According to our research, CARA stock is a bad long-term investment. CARA share price has been in a bear cycle for the past year. Cara Therapeutics, Inc. stock trend is negative. Cara Therapeutics company info. Industry:Cara Therapeutics Inc. analyst ratings, historical stock prices, earnings estimates & actuals. CARA updated stock price target summary.

Complete Cara Therapeutics Inc. stock information by Barron's. View real-time CARA stock price and news, along with industry-best analysis. Cara Therapeutics, Inc. ( NASDAQ:CARA ) shareholders will have a reason to smile today, with the analysts making... Find the latest Cara Therapeutics, Inc. (CARA) stock quote, history, news and other vital information to help you with your stock trading and investing.In this Motley Fool Live video recorded on Aug. 25, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not Cara stock is a buy after the big news. When our award ...Instagram:https://instagram. how much is a 1971 silver half dollar worthnu stocicln holdingsaaa renters insurance review Find the latest Cara Therapeutics, Inc. (CARA) stock quote, history, news and other vital information to help you with your stock trading and investing. best dental insurance for bracesforex com margin requirements 7.26%. $11.7M. Acorda Therapeutics Inc. 6.96%. $12.14M. CARA | Complete Cara Therapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. top fidelity mutual fund Cara Therapeutics' Q4 earnings EPS loss was $0.56 per share. Read why I am looking to quickly book some profits in CARA stock.